Patents Examined by James H. Reamer
  • Pharmaceutical composition based on cocaethylene and use thereof for treating psychoactive substance dependence
    Patent number: 6635237
    Abstract: The present invention relates to a pharmaceutical composition comprising cocaethylene as active ingredient and to its use in treating dependence on psychoactive substances, in particular on cocaine.
    Type: Grant
    Filed: June 10, 2002
    Date of Patent: October 21, 2003
    Assignee: Debussy Holding SA
    Inventors: William Lowenstein, Mario Sanchez, Benedicte Lepere-Prevot, Benjamin De Rothschild
  • Methods for inhibiting angiogenesis
    Patent number: 6632798
    Abstract: Methods for inhibiting angiogenisis are disclosed the comprise administering oleouropein and/or the products of its hydrolysis in therapeutically effective amounts. The methods and compositions of the present invention are particularly effective in inhibiting the vascularization of endothelial cells, and may be utilized to treat a wide variety of cancers, ocular diseases, and inflammatory conditions.
    Type: Grant
    Filed: May 22, 2002
    Date of Patent: October 14, 2003
    Assignee: Antigen Biologicals Corporation
    Inventors: Hamdi K. Hamdi, Jeffrey H. Tavis, Raquel Castellon
  • Lipoxin analogs as novel inhibitors of angiogenesis
    Patent number: 6627658
    Abstract: The present invention is directed to methods for the prevention or inhibition of angiogenesis. The method is accomplished by the administration of an effective amount of 15-epi-16-(para-fluoro)-phenoxy-lipoxin A4, LXA4, 15-epi-LXA4 or 15-R/S-methyl, LXA4 and pharmaceutically acceptable salts, esters, amides, carboxylic acids, or prodrugs thereof, to a subject in need thereof. As a consequence of the action of the therapeutic agent, angiogenesis is prevented or inhibited in the subject.
    Type: Grant
    Filed: March 1, 2002
    Date of Patent: September 30, 2003
    Assignee: The Brigham and Women's Hospital
    Inventors: Charles N. Serhan, Iolanda M. Fierro
  • Preventing desensitization of receptors
    Patent number: 6627602
    Abstract: Desensitization of receptors that control disease is prevented by inhibiting G-protein receptor kinases. This has applicability, e.g., for patients with heart failure or on a left ventricular heart device or a heart pump after surgery or about to undergo surgery and at high risk for a cardiac event or on an opiate or addicted to opiate or with cystic fibrosis or rheumatoid arthritis.
    Type: Grant
    Filed: October 25, 2002
    Date of Patent: September 30, 2003
    Assignee: Duke University
    Inventors: Jonathan S. Stamler, Robert J. Lefkowitz, Erin J. Whalen, Walter J. Koch, Claude A. Piantadosi
  • Sequential therapy comprising a 20(S)-camptothecin and an anthracycline
    Patent number: 6627614
    Abstract: A method is provided for treating a patient having a disease associated with undesirable or uncontrolled cell proliferation. The method comprises: administering to the patient an anthracycline for a period of time during which a 20(S)-camptothecin is not present in a pharmacologically active form in patient's blood; and administering a 20(S)-camptothecin to the patient.
    Type: Grant
    Filed: June 5, 2002
    Date of Patent: September 30, 2003
    Assignee: Super Gen, Inc.
    Inventor: Joseph Rubinfeld
  • Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
    Patent number: 6623736
    Abstract: Interleukin (IL) antagonists are provided for the treatment in humans of neurological disorders, trauma, injuries or compression; neurodegenerative disorders including Alzheimer's Disease; demyelinating neurological disorders including multiple sclerosis; retinal disorders; and muscular disorders. The IL antagonists are used to treat these disorders by inhibiting the action of IL in the human body. The administration of these IL antagonists is performed by intrathecal administration; intracerebroventricular administration; intranasal administration; by inhalation; or by alternative routes of administration.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: September 23, 2003
    Inventor: Edward L. Tobinick
  • Synergistic combination
    Patent number: 6624181
    Abstract: The invention relates to the combined administration of PDE inhibitors and &bgr;2 adrenoceptor agonists for the treatment of respiratory tract disorders.
    Type: Grant
    Filed: February 20, 2002
    Date of Patent: September 23, 2003
    Assignee: Altana Pharma AG
    Inventors: Ulrich Kilian, Christian Schudt
  • Methods and kits for improving vascular health
    Patent number: 6620806
    Abstract: The present invention provides methods and kits for improving or maintaining vascular health, including preventing myocardial infarction or stroke; maintaining or improving vascular reactivity; treating acute or chronic renal failure, peripheral arterial occlusive disease, coronary artery disease, or Raynaud's phenomenon; or lowering plasma levels of Lp(a) using an estrogen agonist/antagonist.
    Type: Grant
    Filed: October 15, 2001
    Date of Patent: September 16, 2003
    Assignee: Pfizer Inc.
    Inventors: Wesley W. Day, Andrew G. Lee, David D. Thompson
  • Treatment of infectious disease using interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family inhibitors
    Patent number: 6610683
    Abstract: The present invention provides methods and compositions for treating infectious disease or suppressing inflammation associated therewith or ameliorating symptoms thereof by the suppression of the activity of a member of the interleukin-1&bgr;-converting enzyme (ICE)/CED-3 family of proteases. Also provided are compositions useful for these purposes. Exemplary compounds useful in the methods of the invention are provided herein.
    Type: Grant
    Filed: November 13, 2001
    Date of Patent: August 26, 2003
    Assignee: IDUN Pharmaceuticals, Inc.
    Inventors: Lawrence C. Fritz, Kevin J. Tomaselli, Donald S. Karanewsky, Steven D. Linton, Xu Bai
  • Compositions and agents for modulating cellular proliferation and angiogenesis
    Patent number: 6610726
    Abstract: The invention is directed to pharmaceutical compositions containing small organic molecules having the ability to mimic or agonize hepatocyte growth factor/scatter factor (HGF/SF) activity, useful for promoting, for example, vascularization of tissues or organs for promoting wound or tissue healing, or augmenting or restoring blood flow to ischemic tissues such as the heart following myocardial infarction.
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: August 26, 2003
    Assignee: North Shore-Long Island Jewish Research Institute
    Inventors: Sivaram Pillarisetti, Itzhak D. Goldberg
  • Use of 2-hydroxy-4-trifluoromethyl-benzoic acid derivatives as inhibitors of the activation of the nuclear transcription factor NF-KS
    Patent number: 6610745
    Abstract: Neurodegenerative diseases, such as dementia, including Alzheimer's disease, can be treated or prevented by administering an effective amount of triflusal or its metabolite, or a pharmaceutically acceptable salt or a prodrug thereof.
    Type: Grant
    Filed: April 4, 2002
    Date of Patent: August 26, 2003
    Assignee: J. Uriach & Cia, S.A.
    Inventors: Manuel Merlos Roca, Alberto Fernandez De Arriba, Fernando Cavalcanti De Maria, Agustí Miralles Acosta, Mariano Sanchez Crespo, Julián Garcia Rafanell, Javier Forn Dalmau
  • Method for increasing the concentration of ascorbic acid in brain tissues of a subject
    Patent number: 6608106
    Abstract: This invention provides a method for increasing the concentration of ascorbic acid in the cells of a subject which comprises administering to the subject an amount of dehydroascorbic acid effective to increase the concentration of ascorbic acid in the subject's cells. This invention further provides a method for increasing the antioxidant potential of the cells of a subject which comprises administering to the subject an amount of dehydroascorbic acid effective to increase the antioxidant potential of the subject's cells. This invention also provides a method for increasing the concentration of ascorbic acid in brain tissue of a subject which comprises administering to the subject an amount of dehydroascorbic acid effective to increase the concentration of ascorbic acid in the subject's brain tissue.
    Type: Grant
    Filed: June 13, 2001
    Date of Patent: August 19, 2003
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: David B. Agus, Juan C. Vera, David W. Golde
  • Method for treatment of tumors using nordihydroguaiaretic acid derivatives
    Patent number: 6608108
    Abstract: Use of nordihydroguaiaretic derivatives to suppress CDC-2 and survivin, stimulate apoptosis, and treat tumors.
    Type: Grant
    Filed: May 9, 2001
    Date of Patent: August 19, 2003
    Assignee: Johns Hopkins University
    Inventors: Ru Chih C. Huang, Jonathan D. Heller, Chih-Chuan Chang
  • Methods and compositions to treat conditions associated with neovascularization
    Patent number: 6608107
    Abstract: This invention also provides a method to inhibit neovascularization in tissue by delivering to the cell or tissue an effective amount of gossypol, or a pharmaceutically acceptable salt, derivative or prodrug thereof. Also provided herein is a method for treating a disease associated with hyproliferation of endothelial cells and/or neovascularization by administering to a subject an effective amount of gossypol, or a pharmaceutically acceptable salt, derivative or prodrug thereof. Kits to treat patients are provided as well.
    Type: Grant
    Filed: December 14, 2001
    Date of Patent: August 19, 2003
    Assignee: Wackvom Limited
    Inventors: Kin-Ping Wong, Ming-Chung Wong
  • Method of using 5-(arysulfonyl)-, 5-(arylsulfanyl)-and 5-(arylsulfanyl)thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
    Patent number: 6605628
    Abstract: This invention relates to a method of using novel 5-(arylsulfonyl)-5-(arylsulfinyl)- and 5-(arylsulfanyl)thiazolidine-2,4-diones of Formula (I), wherein Ar, Ar′, R6, m and n are as defined in the specification as inhibitors of Ras FPTase, and may be used as an alternative to, or in conjunction with, traditional cancer therapy for treating ras- oncogene-dependent tumors, such as cancers of the pancreas, colon, bladder, and thyroid
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: August 12, 2003
    Assignee: Wyeth Holdings Corporation
    Inventors: Semiramis Ayral-Kaloustian, Joseph William Epstein, Gary H. Birnberg, Edward James Salaski, Gloria Jean Macewan, Katherine Cheung
  • Treatments for restless legs syndrome
    Patent number: 6602868
    Abstract: The invention provides methods and use of heterocyclic amines, and phenylazacycloalkane compounds, and their pharmacologically acceptable salts for the treatment of Restless Legs Syndrome (RLS).
    Type: Grant
    Filed: October 29, 2001
    Date of Patent: August 5, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Sylvia McBrinn, Richard Wayne Anderson
  • Treating allergic and inflammatory conditions
    Patent number: 6599913
    Abstract: A method of treating and/or preventing allergic and inflammatory conditions of the skin or airway passages in a human in need of such treating and/or preventing which comprises administering to said human an effective amount of a nonsedating antihistamine for such treating and/or preventing while avoiding the side effects associated with other nonsedating antihistamines that bind to the P-glycoprotein pump and/or the organic anion transport polypeptide pump is disclosed.
    Type: Grant
    Filed: June 21, 2002
    Date of Patent: July 29, 2003
    Assignee: Schering Corporation
    Inventors: William W. Johnson, Er-Jia Wang, Christopher Casciano, Robert P. Clement
  • Anti-HIV compositions
    Patent number: 6596720
    Abstract: The present invention provides: an anti-HIV composition comprising at least one member selected from the group consisting of trifluridine and derivatives thereof, and a pharmaceutically acceptable carrier; an anti-HIV composition comprising (a) at least one member selected from the group consisting of trifluridine and derivatives thereof, (b) a thymidine phosphorylase inhibitor, and a pharmaceutically acceptable carrier; and a composition for potentiating the anti-HIV activity of trifluridine and derivatives thereof, comprising a thymidine phosphorylase inhibitor and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: July 22, 2003
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Hiroo Hoshino, Kenji Kitazato, Masakazu Fukushima
  • Water soluble film for oral administration with instant wettability
    Patent number: 6592887
    Abstract: A composition containing therapeutic agents and/or breath freshening agents for use in the oral cavity is disclosed. The carrier comprises water-soluble polymers in combination with certain ingredients and provides a therapeutic and/or cosmetic effect. The film is coated and dried utilizing existing coating technology and exhibits instant wettability followed by rapid dissolution/disintegration upon administration in the oral cavity.
    Type: Grant
    Filed: June 5, 2002
    Date of Patent: July 15, 2003
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Horst Georg Zerbe, Jian-Hwa Guo, Anthony Serino
  • Small-molecule modulators of hepatocyte growth factor/scatter factor activities
    Patent number: 6589997
    Abstract: The invention is directed to small organic molecules having the ability to mimic or agonize hepatocyte growth factor/scatter factor (HGF/SF) activity, or inhibit or antagonize HGF/SF activity, the former useful for promoting, for example, vascularization of tissues or organs for promoting wound or tissue healing, or augmenting or restoring blood flow to ischemic tissues such as the heart following myocardial infarction. Inhibition of cellular growth or proliferation is beneficial in the treatment, for example, of inflammatory diseases such as inflammatory joint and skin diseases, and dysproliferative diseases such as cancer.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: July 8, 2003
    Assignee: North Shore-Long Island Jewish Health System
    Inventors: Sivaram Pillarisetti, Itzhak D. Goldberg